Review



human bmscs young healthy individuals sexes  (STEMCELL Technologies Inc)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    STEMCELL Technologies Inc human bmscs young healthy individuals sexes
    Impact of Denosumab treatment on the mineralization capacity of <t>human</t> <t>BMSCs.</t> a Representative image of ARS-stained cultures of human BMSCs from healthy donors after 2 weeks of culture either in basal medium (CTR) or in OIM alone or in OIM + isotype control (OIM + ISO) or in OIM + Denosumab (OIM + Dmab); in all the conditions, the culture medium was changed twice a week. At the end, the mineral deposition was quantified and indicated by Abs reading at 405 nm. Scale bar: 500 μm. Higher magnifications are provided in Figure . b Gene expression analysis of representative osteogenic genes in human BMSCs in the different treatment conditions indicated; normalization on 18 S. Results are expressed as Arbitrary Units (A.U.). All the data are represented as mean ± SEM. * p < 0.05; a: Friedman test; b: Kruskal-Wallis test. CTR: control. OIM: Osteogenic Induction Medium. ISO: isotype control. Dmab: Denosumab
    Human Bmscs Young Healthy Individuals Sexes, supplied by STEMCELL Technologies Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human bmscs young healthy individuals sexes/product/STEMCELL Technologies Inc
    Average 90 stars, based on 1 article reviews
    human bmscs young healthy individuals sexes - by Bioz Stars, 2026-03
    90/100 stars

    Images

    1) Product Images from "Rankl genetic deficiency and functional blockade undermine skeletal stem and progenitor cell differentiation"

    Article Title: Rankl genetic deficiency and functional blockade undermine skeletal stem and progenitor cell differentiation

    Journal: Stem Cell Research & Therapy

    doi: 10.1186/s13287-024-03803-3

    Impact of Denosumab treatment on the mineralization capacity of human BMSCs. a Representative image of ARS-stained cultures of human BMSCs from healthy donors after 2 weeks of culture either in basal medium (CTR) or in OIM alone or in OIM + isotype control (OIM + ISO) or in OIM + Denosumab (OIM + Dmab); in all the conditions, the culture medium was changed twice a week. At the end, the mineral deposition was quantified and indicated by Abs reading at 405 nm. Scale bar: 500 μm. Higher magnifications are provided in Figure . b Gene expression analysis of representative osteogenic genes in human BMSCs in the different treatment conditions indicated; normalization on 18 S. Results are expressed as Arbitrary Units (A.U.). All the data are represented as mean ± SEM. * p < 0.05; a: Friedman test; b: Kruskal-Wallis test. CTR: control. OIM: Osteogenic Induction Medium. ISO: isotype control. Dmab: Denosumab
    Figure Legend Snippet: Impact of Denosumab treatment on the mineralization capacity of human BMSCs. a Representative image of ARS-stained cultures of human BMSCs from healthy donors after 2 weeks of culture either in basal medium (CTR) or in OIM alone or in OIM + isotype control (OIM + ISO) or in OIM + Denosumab (OIM + Dmab); in all the conditions, the culture medium was changed twice a week. At the end, the mineral deposition was quantified and indicated by Abs reading at 405 nm. Scale bar: 500 μm. Higher magnifications are provided in Figure . b Gene expression analysis of representative osteogenic genes in human BMSCs in the different treatment conditions indicated; normalization on 18 S. Results are expressed as Arbitrary Units (A.U.). All the data are represented as mean ± SEM. * p < 0.05; a: Friedman test; b: Kruskal-Wallis test. CTR: control. OIM: Osteogenic Induction Medium. ISO: isotype control. Dmab: Denosumab

    Techniques Used: Staining, Control, Expressing



    Similar Products

    human bmscs young healthy individuals sexes  (STEMCELL Technologies Inc)
    90
    STEMCELL Technologies Inc human bmscs young healthy individuals sexes
    Impact of Denosumab treatment on the mineralization capacity of <t>human</t> <t>BMSCs.</t> a Representative image of ARS-stained cultures of human BMSCs from healthy donors after 2 weeks of culture either in basal medium (CTR) or in OIM alone or in OIM + isotype control (OIM + ISO) or in OIM + Denosumab (OIM + Dmab); in all the conditions, the culture medium was changed twice a week. At the end, the mineral deposition was quantified and indicated by Abs reading at 405 nm. Scale bar: 500 μm. Higher magnifications are provided in Figure . b Gene expression analysis of representative osteogenic genes in human BMSCs in the different treatment conditions indicated; normalization on 18 S. Results are expressed as Arbitrary Units (A.U.). All the data are represented as mean ± SEM. * p < 0.05; a: Friedman test; b: Kruskal-Wallis test. CTR: control. OIM: Osteogenic Induction Medium. ISO: isotype control. Dmab: Denosumab
    Human Bmscs Young Healthy Individuals Sexes, supplied by STEMCELL Technologies Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human bmscs young healthy individuals sexes/product/STEMCELL Technologies Inc
    Average 90 stars, based on 1 article reviews
    human bmscs young healthy individuals sexes - by Bioz Stars, 2026-03
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Impact of Denosumab treatment on the mineralization capacity of human BMSCs. a Representative image of ARS-stained cultures of human BMSCs from healthy donors after 2 weeks of culture either in basal medium (CTR) or in OIM alone or in OIM + isotype control (OIM + ISO) or in OIM + Denosumab (OIM + Dmab); in all the conditions, the culture medium was changed twice a week. At the end, the mineral deposition was quantified and indicated by Abs reading at 405 nm. Scale bar: 500 μm. Higher magnifications are provided in Figure . b Gene expression analysis of representative osteogenic genes in human BMSCs in the different treatment conditions indicated; normalization on 18 S. Results are expressed as Arbitrary Units (A.U.). All the data are represented as mean ± SEM. * p < 0.05; a: Friedman test; b: Kruskal-Wallis test. CTR: control. OIM: Osteogenic Induction Medium. ISO: isotype control. Dmab: Denosumab

    Journal: Stem Cell Research & Therapy

    Article Title: Rankl genetic deficiency and functional blockade undermine skeletal stem and progenitor cell differentiation

    doi: 10.1186/s13287-024-03803-3

    Figure Lengend Snippet: Impact of Denosumab treatment on the mineralization capacity of human BMSCs. a Representative image of ARS-stained cultures of human BMSCs from healthy donors after 2 weeks of culture either in basal medium (CTR) or in OIM alone or in OIM + isotype control (OIM + ISO) or in OIM + Denosumab (OIM + Dmab); in all the conditions, the culture medium was changed twice a week. At the end, the mineral deposition was quantified and indicated by Abs reading at 405 nm. Scale bar: 500 μm. Higher magnifications are provided in Figure . b Gene expression analysis of representative osteogenic genes in human BMSCs in the different treatment conditions indicated; normalization on 18 S. Results are expressed as Arbitrary Units (A.U.). All the data are represented as mean ± SEM. * p < 0.05; a: Friedman test; b: Kruskal-Wallis test. CTR: control. OIM: Osteogenic Induction Medium. ISO: isotype control. Dmab: Denosumab

    Article Snippet: Human BMSCs from young healthy individuals of both sexes were purchased from Stem Cell Technologies (cat. #70,071).

    Techniques: Staining, Control, Expressing